Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chemotherapy

Maintenance therapy in breast cancer—many questions remain

A recent clinical trial showed that a significant progression-free and overall survival benefit was associated with maintenance chemotherapy in patients with HER2-negative metastatic breast cancer who have disease control after six cycles of conventional chemotherapy. However, the choice of observation alone as the control arm limits the clinical application of these data.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Park, Y. H. et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.45.2490.

  2. Alba, E. et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001–01 study. Breast Cancer Res. Treat. 122, 169–176 (2010).

    Article  CAS  Google Scholar 

  3. Gennari, A. et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J. Clin. Oncol. 24, 3912–3918 (2006).

    Article  CAS  Google Scholar 

  4. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)® Breast Cancer [online], (2013).

  5. Bertelli, G. et al. Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer. Oncology 68, 364–370 (2005).

    Article  CAS  Google Scholar 

  6. Dufresne, A. et al. Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer. Int. J. Med. Sci. 5, 100–105 (2008).

    Article  CAS  Google Scholar 

  7. Seidman, A. D. The search for an elusive uniform strategy for a heterogeneous disease: lesson learned? J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2013.48.6894.

  8. Broglio, K. B. & Berry, D. A. Detecting an overall survival benefit that is derived from progression-free survival. J. Natl Cancer Inst. 101, 1642–1649 (2009).

    Article  Google Scholar 

  9. OShaughnessy, J. et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC) [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a1005 (2010).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Miguel Martín.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martín, M., López-Tarruella, S. Maintenance therapy in breast cancer—many questions remain. Nat Rev Clin Oncol 10, 370–372 (2013). https://doi.org/10.1038/nrclinonc.2013.87

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.87

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer